Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031798 · ClinicalTrials.gov registry record · Phase 3
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00031798: Clinical Trial Phase 3 study, sponsored by Wake Forest University Health Sciences.
NCT00031798 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031798, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet known if methylphenidate is effective in improving quality of life in patients with primary or metastatic brain tumors. PURPOSE: Randomized phase III trial to determine the effectiveness of methylphenidate in improving quality of life in patients who have brain tumors and are undergoing radiation therapy.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- DRUG methylphenidate hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04-01 |
| Est. Completion | 2006-05-01 |
| Phase | Phase 3 |
Why NCT00031798 stopped before completion
NCT00031798 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00031798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031798 about?
NCT00031798 is a clinical study titled "Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors". RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet known if methylphenidate is effective in improving quality of life in patients with primary or metastatic brain tumors. PURPOSE: Randomized phase III trial to determine the effectiveness of methylphenidate in i...
What is the current status of trial NCT00031798?
This trial is currently terminated. It is a Phase 3 study. The study started on 2002-04-01. Estimated completion is 2006-05-01.
What interventions are being tested in trial NCT00031798?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), methylphenidate hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00031798?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI